ABBVIE
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 338
- Registration Number
- NCT02955212
- Locations
- 🇧🇷
Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 152964, Curitiba, Parana, Brazil
🇰🇷Kyungpook National Univ Hosp /ID# 166919, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇨🇳Anhui Provincial Hospital /ID# 161117, Hefei, Anhui, China
A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT02955251
- Locations
- 🇫🇷
Centre Leon Berard /ID# 168072, Lyon CEDEX 08, Rhone, France
🇫🇷Gustave Roussy /ID# 162257, Villejuif, Ile-de-France, France
🇺🇸HonorHealth Research Institute - Pima /ID# 155461, Scottsdale, Arizona, United States
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02951117
- Locations
- 🇦🇺
St Vincent´s Hospital /ID# 153022, Darlinghurst, Australia
🇦🇺The Alfred Hospital /ID# 150202, Prahran, Australia
🇦🇺St. Vincents Hospital Melbourne /ID# 157925, Fitzroy, Australia
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
- Conditions
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 449
- Registration Number
- NCT02945228
- Locations
- 🇯🇵
Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 167688, Osaka-shi, Osaka, Japan
🇯🇵Osaka Medical College Hospital /ID# 162908, Takatsuki -shi, Osaka, Japan
🇯🇵Osaka Red Cross Hospital /ID# 161888, Osaka-shi, Osaka, Japan
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 25
- Registration Number
- NCT02944396
- Locations
- 🇺🇸
University of Chicago /ID# 153824, Chicago, Illinois, United States
🇺🇸Duke University Medical Center /ID# 153821, Durham, North Carolina, United States
🇺🇸University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama, United States
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 129
- Registration Number
- NCT02942290
- Locations
- 🇺🇸
Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT02939989
- Locations
- 🇺🇸
Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States
🇨🇳Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing, China
🇨🇦University of Calgary /ID# 155726, Calgary, Alberta, Canada
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 433
- Registration Number
- NCT02925494
- Locations
- 🇺🇸
Choice Research, LLC /ID# 153492, Dothan, Alabama, United States
🇺🇸NECCR Fall River LLC /ID# 153274, Fall River, Massachusetts, United States
🇺🇸Mount Vernon Clinical Res, LLC /ID# 153403, Atlanta, Georgia, United States
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 167
- Registration Number
- NCT02925117
- Locations
- 🇺🇸
Advanced Medical Research /ID# 154516, Sandy Springs, Georgia, United States
🇺🇸ForCare Clinical Research /ID# 157974, Tampa, Florida, United States
🇺🇸DermAssociates /ID# 153584, Rockville, Maryland, United States
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
- Conditions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 259
- Registration Number
- NCT02916017
- Locations
- 🇯🇵
Nippon Medical School Hospital /ID# 166938, Bunkyo-ku, Tokyo, Japan
🇯🇵The University of Tokyo Hospital /ID# 162943, Bunkyo-ku, Tokyo, Japan
🇯🇵Tokyo Medical University Hospital /ID# 164146, Shinjuku-ku, Tokyo, Japan